The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 22nd 2024
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
Dr. Long on Treating Melanoma With Dabrafenib Plus Trametinib
November 17th 2016Georgina V. Long, BSc, PhD, MBBS, chair of Melanoma Medical Oncology and Translational Research at the Melanoma Institute of Australia (MIA) and Royal North Shore Hospital, University of Australia, discusses the patients with melanoma who respond best to the combination of dabrafenib plus trametinib.
Dr. Amaria on Dabrafenib Plus Trametinib in Melanoma
November 10th 2016Rodabe N. Amaria, MD, assistant professor Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the results of a recent trial testing neoadjuvant and adjuvant dabrafenib plus trametinib versus standard of care in high-risk resectable BRAF-mutant melanoma.
SD-101, Pembrolizumab Combo Well-Tolerated in Early-Stage Melanoma
November 10th 2016Results from a safety, tolerability, and dose escalation phase Ib/II study involving intratumoral SD-101 and pembrolizumab (Keytruda) have demonstrated that the combination was well-tolerated with no dose-limiting toxicities.
Perioperative Dabrafenib/Trametinib Improves RFS in Stage III Melanoma
Treatment with the combination of dabrafenib and trametinib before and after surgery demonstrated a dramatic improvement in relapse-free survival compared with the standard of care for patients with stage IIIb/c or oligometastatic BRAF-mutant melanoma.
Dr. Keith Flaherty Discusses Long-Term Data from the COLUMBUS Trial
November 10th 2016Keith T. Flaherty, MD, director of the Termeer Center for Targeted Therapy, Massachusetts General Hospital and professor of Medicine, Harvard Medical School, discusses the results from the COLUMBUS trial, testing encorafenib plus binimetinib compared to vemurafenib or encorafenib as single agents.
Bin Zheng on the Potential of Diabetes Drugs in Melanoma
November 10th 2016Bin Zheng, PhD, assistant professor of Dermatology at Harvard Medical School and assistant biologist at Massachusetts General Hospital, discusses the potential for phenformin, a drug created for Type 2 diabetes, to be used for patients with melanoma.
Encorafenib/Binimetinib Highly Effective in BRAF-mutant Melanoma
The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib reduced the risk of progression or death by 46% compared with vemurafenib (Zelboraf) for patients with BRAF-mutant unresectable melanoma.
Dabrafenib/Trametinib OS Duration Associated With Number of Metastatic Melanoma Sites
November 9th 2016The combination of dabrafenib and trametinib continued to demonstrate durable efficacy for patients with BRAF V600E/K-mutant melanoma across patient subgroups in a 3-year analysis of the phase III COMBI-d study, with baseline site of metastasis identified as a predictor of overall survival ≥36 months,
Graham Mann on Genetic Mutations in Different Types of Melanoma
Graham Mann, MBBS, PhD, FRACP, professor of Medicine, Westmead Clinical School and co-director of the Centre for Cancer Research, The Westmead Institute for Medical Research at the University of Sydney in Australia, discusses his findings from the Australian Melanoma Genome Project, which were presented at the 2016 Society for Melanoma Research (SMR) Congress.
Expert Highlights Resistance to Targeted Therapies, Role of Epigenetic Changes in Melanoma
November 8th 2016Helmut Schiader, MD, discusses why drug resistance may be due to epigenetic changes and not mutation-induced changes, as well as the role of immunotherapy/targeted therapy combinations in combating resistance.
Dr. Christian Blank on Combining Immunotherapy Agents in High-Risk Melanoma
November 8th 2016Christian Blank, MD, PhD, Netherlands Cancer Institute, discusses some of the early findings from the OpACIN trial testing a combination of ipilimumab and nivolumab in the neoadjuvant and adjuvant setting for patients with stage III melanoma.
Neoadjuvant Nivolumab/Ipilimumab Shows Early Promise for Stage III Melanoma
Neoadjuvant therapy with the combination of nivolumab and ipilimumab is plausible and effective but can induce a high level of adverse events calling for further research into better tolerated dosing schemes.